CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Prognostic value of T regulatory cells and immune checkpoints expression in tumor-draining lymph nodes for oral squamous cell carcinoma.
Prognostic value of T regulatory cells and immune checkpoints expression in tumor-draining lymph nodes for oral squamous cell carcinoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
这些发现凸显了 TDLNs 在 OSCC 免疫微环境中的关键作用,并确立 T 细胞上免疫检查点表达作为有前景的预后生物标志物。这些见解提升了 OSCC 的预后框架,并为个体化治疗策略铺平了道路。TDLNs 的预后意义以及免疫检查点抑制剂的高表达,为采用新辅助免疫治疗提供了有力论据。
共纳入49例OSCC患者。每位患者分析一个TDLN,采用流式细胞术分析CD4+、CD8+和Tregs上的免疫检查点表达(PD-1、CTLA-4、TIGIT、TIM-3、LAG-3)及其他标志物如CD69、CXCR5。评估无病生存期(DFS)和总生存期(OS)。
根据多因素分析,TDLNs中FoxP3+CD4+和TIGIT+CD8+细胞水平升高与显著较差的DFS相关,而高CXCR5+CD4+水平与较好的DFS相关。值得注意的是,TDLNs内T细胞上免疫检查点的表达与复发状态显示出显著关联。经历复发的患者在TDLNs中表现出更高水平的T调节细胞、CD4+PD-1+和CD4+CTLA-4+细胞。生存多因素分析显示,T状态成为OS的独立预测因子。
Forty-nine OSCC patients were enrolled. One TDLN per patient was analysed using flow cytometry to profile immune-checkpoint expression (PD-1, CTLA-4, TIGIT, TIM-3, LAG-3) and other markers such as CD69, CXCR5 on CD4+, CD8+, and Tregs. Disease-free survival (DFS) and overall survival (OS) were assessed.
According to multivariate analysis, elevated levels of FoxP3+CD4+ and TIGIT+CD8+ cells in TDLNs correlated with significantly worse DFS, while high CXCR5+CD4+ levels were associated with better DFS. Notably, the expression of immune checkpoints on T cells within TDLNs showed significant associations with recurrence status. Patients experiencing recurrence exhibited heightened levels of T regulatory cells, CD4+PD-1+ and CD4+CTLA-4+, cells in TDLNs. Survival multivariate analyses revealed that T status emerged as an independent predictor of OS.
The findings highlight the critical role of TDLNs in the immune microenvironment of OSCC and establish immune checkpoint expression on T cells as promising prognostic biomarkers. These insights upgrade the prognostic framework for OSCC and pave the way for individualized therapeutic strategies. The prognostic significance of TDLNs and a high expression of immune checkpoint inhibitors is a compelling argument for the adoption of neoadjuvant immunotherapy.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。